<DOC>
	<DOCNO>NCT01281566</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness Cisapride improve feed problem premature newborn infant .</brief_summary>
	<brief_title>A Study Cisapride Premature Infants With Feeding Problems</brief_title>
	<detailed_description>This double-blind study identity treatment assign ( Cisapride placebo ) know patient 's legal guardian study staff involve study . Patients randomize ( assigned chance ) receive either drug Cisapride placebo ( placebo identical appearance Cisapride contain Cisapride active drug ) see Cisapride effective improve feed problem ( refer feed intolerance ) premature newborn infant tolerate oral feed mouth tube go directly stomach intestine . Patients give either cisapride dose 0.2 mg/kg placebo liquid suspension tube nose stomach ( refer nasogastric tube ) 15 minute feed every 6 hour ( 4 time day refer q.i.d . schedule ) .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Cisapride</mesh_term>
	<criteria>Must hospitalize continuous cardiac monitoring duration study Patient demonstrate feed intolerance define protocol Patient 's parent legal guardian must sign informed consent form Currently active significant cardiovascular disease , determine neonatologist/physician , include congenital heart disease heart block ( patent ductus arteriosus without cardiac compromise time randomization acceptable )</criteria>
	<gender>All</gender>
	<minimum_age>36 Weeks</minimum_age>
	<maximum_age>99 Weeks</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Cisapride ( Prepulsid )</keyword>
	<keyword>Feeding intolerance</keyword>
	<keyword>Enteral feeding</keyword>
	<keyword>Nasogastric tube</keyword>
	<keyword>Neonate</keyword>
</DOC>